{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:16Z","timestamp":1777870336602,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-02159-4","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T10:27:00Z","timestamp":1733048820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opioid use and poisoning in hospitalized patients with chronic kidney disease"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-9494","authenticated-orcid":false,"given":"Nadim","family":"Zaidan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Jalloul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba","family":"Azar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"El-Sayegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"issue":"9","key":"2159_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/pds.1276","volume":"15","author":"LJ Paulozzi","year":"2006","unstructured":"Paulozzi LJ, Budnitz DS, Xi Y (2006) Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 15(9):618\u2013627. https:\/\/doi.org\/10.1002\/pds.1276","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2159_CR2","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.eclinm.2023.102079","volume":"61","author":"S Fujita-Imazu","year":"2023","unstructured":"Fujita-Imazu S, Xie J, Dhungel B et al (2023) Evolving trends in drug overdose mortality in the USA from 2000 to 2020: an age-period-cohort analysis. EClinicalMedicine. 61:102079. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102079. (Published 2023 Jul 6)","journal-title":"EClinicalMedicine."},{"issue":"6","key":"2159_CR3","doi-asserted-by":"publisher","first-page":"e196373","DOI":"10.1001\/jamanetworkopen.2019.6373","volume":"2","author":"RL Haffajee","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE (2019) Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open 2(6):e196373. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6373. (Published 2019 Jun 5)","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2159_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/pm\/pnx009","volume":"19","author":"BK Zedler","year":"2018","unstructured":"Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL (2018) Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med 19(1):68\u201378. https:\/\/doi.org\/10.1093\/pm\/pnx009","journal-title":"Pain Med"},{"issue":"5","key":"2159_CR5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","volume":"125","author":"LR Webster","year":"2017","unstructured":"Webster LR (2017) Risk factors for opioid-use disorder and overdose. Anesth Analg 125(5):1741\u20131748. https:\/\/doi.org\/10.1213\/ANE.0000000000002496","journal-title":"Anesth Analg"},{"issue":"6","key":"2159_CR6","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67(6):2089\u20132100. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00365.x","journal-title":"Kidney Int"},{"issue":"7","key":"2159_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","volume":"84","author":"HS Smith","year":"2009","unstructured":"Smith HS (2009) Opioid metabolism. Mayo Clin Proc 84(7):613\u2013624. https:\/\/doi.org\/10.1016\/S0025-6196(11)60750-7","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2159_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.1993.127","volume":"54","author":"R Osborne","year":"1993","unstructured":"Osborne R, Joel S, Grebenik K, Trew D, Slevin M (1993) The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54(2):158\u2013167. https:\/\/doi.org\/10.1038\/clpt.1993.127","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2159_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2215\/CJN.13341019","volume":"15","author":"AD Muzaale","year":"2020","unstructured":"Muzaale AD, Daubresse M, Bae S et al (2020) Benzodiazepines, codispensed opioids, and mortality among patients initiating long-term in-center hemodialysis. Clin J Am Soc Nephrol 15(6):794\u2013804. https:\/\/doi.org\/10.2215\/CJN.13341019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2159_CR10","doi-asserted-by":"publisher","first-page":"e2016839","DOI":"10.1001\/jamanetworkopen.2020.16839","volume":"3","author":"Y Han","year":"2020","unstructured":"Han Y, Balkrishnan R, Hirth RA et al (2020) Assessment of prescription analgesic use in older adults with and without chronic kidney disease and outcomes. JAMA Netw Open 3(9):e2016839. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.16839. (Published 2020 Sep 1)","journal-title":"JAMA Netw Open"},{"key":"2159_CR11","unstructured":"https:\/\/usrds-adr.niddk.nih.gov\/2023\/chronic-kidney-disease\/7-prescription-drug-coverage-in-patients-with-ckd. Accessed 1 May 2024"},{"key":"2159_CR12","unstructured":"https:\/\/usrds-adr.niddk.nih.gov\/2023\/end-stage-renal-disease\/10-prescription-drug-coverage-in-patients-with-esrd. Accessed 1 May 2024"},{"issue":"2","key":"2159_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/sdi.12196","volume":"27","author":"SN Davison","year":"2014","unstructured":"Davison SN, Koncicki H, Brennan F (2014) Pain in chronic kidney disease: a scoping review. Semin Dial 27(2):188\u2013204. https:\/\/doi.org\/10.1111\/sdi.12196","journal-title":"Semin Dial"},{"issue":"1","key":"2159_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/ijms18010223","volume":"18","author":"M Mallappallil","year":"2017","unstructured":"Mallappallil M, Sabu J, Friedman EA, Salifu M (2017) What do we know about opioids and the kidney? Int J Mol Sci 18(1):223. https:\/\/doi.org\/10.3390\/ijms18010223. (Published 2017 Jan 22)","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2159_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","volume":"76","author":"M Baker","year":"2020","unstructured":"Baker M, Perazella MA (2020) NSAIDs in CKD: are they safe? Am J Kidney Dis 76(4):546\u2013557. https:\/\/doi.org\/10.1053\/j.ajkd.2020.03.023","journal-title":"Am J Kidney Dis"},{"key":"2159_CR16","unstructured":"https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html. Accessed 8 May 2024"},{"issue":"2","key":"2159_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndtplus\/sfp001","volume":"2","author":"PC Pham","year":"2009","unstructured":"Pham PC, Toscano E, Pham PM, Pham PA, Pham SV, Pham PT (2009) Pain management in patients with chronic kidney disease. NDT Plus 2(2):111\u2013118. https:\/\/doi.org\/10.1093\/ndtplus\/sfp001","journal-title":"NDT Plus"},{"issue":"3","key":"2159_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ackd.2005.03.008","volume":"12","author":"SN Davison","year":"2005","unstructured":"Davison SN (2005) Chronic pain in end-stage renal disease. Adv Chron Kidney Dis 12(3):326\u2013334. https:\/\/doi.org\/10.1016\/j.ackd.2005.03.008","journal-title":"Adv Chron Kidney Dis"},{"issue":"6","key":"2159_CR19","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1111\/j.1523-1755.2004.00658.x","volume":"65","author":"GR Bailie","year":"2004","unstructured":"Bailie GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW (2004) Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription. Kidney Int 65(6):2419\u20132425. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00658.x","journal-title":"Kidney Int"},{"issue":"3","key":"2159_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/HYPERTENSIONAHA.114.05105","volume":"66","author":"CC Hsu","year":"2015","unstructured":"Hsu CC, Wang H, Hsu YH et al (2015) Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension 66(3):524\u2013533. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.05105","journal-title":"Hypertension"},{"key":"2159_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/TCRM.S262843","volume":"16","author":"F Coluzzi","year":"2020","unstructured":"Coluzzi F, Caputi FF, Billeci D et al (2020) Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Ther Clin Risk Manag 16:821\u2013837. https:\/\/doi.org\/10.2147\/TCRM.S262843. (Published 2020 Sep 9)","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2159_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","volume":"28","author":"M Dean","year":"2004","unstructured":"Dean M (2004) Opioids in renal failure and dialysis patients. J Pain Symptom Manag 28(5):497\u2013504. https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.02.021","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"2159_CR23","doi-asserted-by":"publisher","first-page":"21356","DOI":"10.1038\/s41598-021-00338-y","volume":"11","author":"T Imaoka","year":"2021","unstructured":"Imaoka T, Huang W, Shum S et al (2021) Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system. Sci Rep 11(1):21356. https:\/\/doi.org\/10.1038\/s41598-021-00338-y. (Published 2021 Nov 1)","journal-title":"Sci Rep"},{"issue":"1","key":"2159_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41398-023-02406-5","volume":"13","author":"MS Milella","year":"2023","unstructured":"Milella MS, D\u2019Ottavio G, De Pirro S, Barra M, Caprioli D, Badiani A (2023) Heroin and its metabolites: relevance to heroin use disorder. Transl Psychiatry 13(1):120. https:\/\/doi.org\/10.1038\/s41398-023-02406-5. (Published 2023 Apr 8)","journal-title":"Transl Psychiatry"},{"issue":"9","key":"2159_CR25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1681\/ASN.0000000000000165","volume":"34","author":"KH Nguyen","year":"2023","unstructured":"Nguyen KH, Buckle-Rashid R, Thorsness R, Agbai CO, Crews DC, Trivedi AN (2023) Structural racism, historical redlining, and incidence of kidney failure in US Cities, 2012\u20132019. J Am Soc Nephrol 34(9):1493\u20131503. https:\/\/doi.org\/10.1681\/ASN.0000000000000165","journal-title":"J Am Soc Nephrol"},{"key":"2159_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugpo.2016.03.003","volume":"32","author":"SR Friedman","year":"2016","unstructured":"Friedman SR, Tempalski B, Brady JE et al (2016) Income inequality, drug-related arrests, and the health of people who inject drugs: reflections on seventeen years of research. Int J Drug Policy 32:11\u201316. https:\/\/doi.org\/10.1016\/j.drugpo.2016.03.003","journal-title":"Int J Drug Policy"},{"issue":"5","key":"2159_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s11524-023-00754-7","volume":"100","author":"LD Williams","year":"2023","unstructured":"Williams LD, Kolak M, Villanueva C, Ompad DC, Tempalski B (2023) Creation and validation of a new socio-built environment index measure of opioid overdose risk for use in both non-urban and urban settings. J Urban Health 100(5):1048\u20131061. https:\/\/doi.org\/10.1007\/s11524-023-00754-7","journal-title":"J Urban Health"},{"issue":"4","key":"2159_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/00333549221108986","volume":"138","author":"JJ Mpofu","year":"2023","unstructured":"Mpofu JJ, Crosby A, Flynn MA et al (2023) Preventing suicidal behavior among American Indian and Alaska native adolescents and young adults. Public Health Rep 138(4):593\u2013601. https:\/\/doi.org\/10.1177\/00333549221108986","journal-title":"Public Health Rep"},{"key":"2159_CR29","unstructured":"https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html. Accessed 12 Oct 2024"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02159-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:06Z","timestamp":1777564446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/2\/531\/8307180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":29,"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02159-4","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosures\u2014Goldfarb: Consultant: Arbor Biotechnologies, Alnylam, Lilac Pharmaceuticals; Research: Novo Nordisk, Travere; Owner: Moonstone Nutrition Inc. All other authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Because of the deidentified nature of the NIS database, this study was considered exempt from requiring an IRB review by the Northwell Health Institutional Review Board (HSRD23-0275-NH).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was done in accordance with the Declaration of Helsinki. It does not involve any animal experiment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}